The 5 most recent market catalysts affecting $BLLN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
CMS is proposing significant changes to Medicare's clinical laboratory fee schedule, aiming to reduce payments by aligning them with private sector rates. This is a long-term initi…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Canaccord Genuity Initiates Coverage On BillionToOne with Buy Rating, Announces Price Target of $120
Canaccord Genuity initiating coverage on BillionToOne with a 'Buy' rating and a $120 price target is a positive development for the company. Analyst coverage, especially with a str…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 95
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move
BillionToOne (BLLN) announced impressive Q2 2026 results, showcasing strong revenue growth, a return to profitability, and increased test volumes. The company also maintained its f…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 65
BillionToOne Affirms FY2026 Sales Guidance of $450.000M-$465.000M vs $456.440M Est
BillionToOne (BLLN) filed an 8-K to affirm its fiscal year 2026 sales guidance, keeping the range at $450 million to $465 million. This is a routine disclosure when a company reite…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
BillionToOne Q3 EPS $0.15 Misses $0.19 Estimate, Sales $109.400M Beat $109.365M Estimate
BillionToOne's Q3 earnings per share of $0.15 missed the analyst consensus of $0.19 by 21.05%, a notable miss that could concern investors regarding profitability. However, the com…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.